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► PET/CT and MRI are equal in predicting myometrial invasion, cervical involvement and lymph node metastases in endometrial cancer patients.
► Transvaginal ultrasound has high specificity and accuracy in predicting myometrial invasion and cervical involvement in endometrial cancer patients.
► Imaging cannot replace surgical staging yet. However, the modalities may be valuable in the multidisciplinary treatment planning.⁎ Corresponding author at: Gynecologic Clinic, Section
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Objectives. The aim of this prospective multicenter study was to evaluate and compare the diagnostic
performance of PET/CT, MRI and transvaginal two-dimensional ultrasound (2DUS) in the preoperative
assessment of endometrial cancer (EC).
Methods. 318 consecutive womenwith EC were included when referred to three Danish tertiary gyneco-
logical centers for surgical treatment. Preoperatively they were PET/CT-, MRI-, and 2DUS scanned. The im-
aging results were compared to the final pathological findings. This study was approved by the National
Committee on Health Research Ethics.
Results. For predicting myometrial invasion, we found sensitivity, specificity, PPV, NPV, and accuracy for
PET/CT to be 93%, 49%, 41%, 95% and 61%, for MRI to be 87%, 57%, 44%, 92%, and 66% and for 2DUS to be 71%,
72%, 51%, 86% and 72%. For predicting cervical invasion, the values were 43%, 94%, 69%, 85% and 83%, respec-
tively, for PET/CT, 33%, 95%, 60%, 85%, and 82%, respectively, for MRI, and 29%, 92%, 48%, 82% and 78% for
2DUS. Finally, for lymph node metastases, the values were 74%, 93%, 59%, 96%, and 91% for PET/CT and
59%, 93%, 40%, 97% and 90% for MRI. When comparing the diagnostic performance we found PET/CT, MRI
and 2DUS to be comparable in predicting myometrial invasion. For cervical invasion and lymph node
metastases, however, PET/CT was the best.4074, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100 København Ø, Denmark. Fax: +45 35 45 42 85.
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301S.L. Antonsen et al. / Gynecologic Oncology 128 (2013) 300–308Conclusions. None of the modalities can yet replace surgical staging. However, they all contributed to
important knowledge and were, furthermore, able to upstage low-risk patients who would not have
been recommended lymph node resection based on histology and grade alone.© 2012 Elsevier Inc. All rights reserved.Introduction
Imaging is important in themultidisciplinarymanagement of uterine
malignancy and includes characterization and staging of tumor, treat-
ment planning, and subsequent follow-up. Endometrial cancer (EC) is
the most common uterine malignancy. The treatment of EC is primarily
surgical, and the extent of surgery relies on the estimated stage and risk
of extra-uterine disease. The most important risk factors for extra-
uterine disease and poor outcome are depth of myometrial invasion
(MI), cervical involvement (CI), tumor grade and histological sub-type,
and lymph nodemetastases (LNM). Amajor obstacle is that these factors
cannot be revealed by clinical examination alone. Therefore, the clinical
challenge is the optimal selection of patients for more extensive surgi-
cal procedures (i.e. lymph node dissection or optimal debulking) inOUH
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pitalet, Copenhagen University Hospatients with high risk of advanced disease and relapses,while avoiding
overtreatment in low-risk patients, as studies have shown that lymph-
adenectomy can induce complications and may not increase survival of
low-risk EC patients [1,2]. A non-invasive technique that identifies LNM
and tumor-extent would be beneficial. However, optimal imaging mo-
dality and practice varies among centers and results are not in agree-
ment [3].
Magnetic resonance imaging (MRI) is considered the most accurate
imaging technique for preoperative assessment of EC because of its
excellent soft-tissue contrast-resolution [4,5]. Unlike ultrasound, MRI
is not operator dependent and unlike computed tomography (CT) it
has no radiation burden [6].
2-[Fluorine 18] flouro-2-deoxy-D-glucose (FDG) positron emission
tomography (PET) is a functional method based on the increasedALL
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pital, OUH: Odense University Hospital, AAL: Aalborg University Hospital.
Table 1
Clinical characteristics of the 318 patients in the ENDOMET study.
N (%)
Stage
AEH 18 (5.7)
IA 172 (54.1)
IB 38 (11.9)
II 36 (11.3)
IIIA 6 (1.9)
IIIB 6 (1.9)
IIIC 24 (7.5)
IVA 2 (0.6)
IVB 16 (5.0)
Histological grade
1 163 (51.3)
2 61 (19.2)
3 24 (7.5)
Not graded 70 (22.0)
Dominant histological type
Atypical hyperplasia 18 (5.6)
Endometrioid adenocarcinoma 253 (79.6)
Serous adenocarcinoma 25 (7.9)
Clear cell carcinoma 4 (1.3)
Carcinosarcoma/sarcoma 16 (5.0)
Undifferentiated adenocarcinoma 2 (0.6)
Myometrial invasiona
b50% 228 (71.7)
≥50% 82 (25.8)
Missing 8 (2.5)
Cervical stromal involvement
Yes 63 (19.8)
No 248 (78.0)
Missing 7 (2.2)
Lymph node metastases
Yes 35 (11.2)
No 122 (38.4)
Not removed 161 (50.6)
AEH: atypical endometrial hyperplasia.
a b50%: superficial+less than 50% myometrial invasion. ≥50%: equal to or more
than 50% myometrial invasion+invasion of serosa.
302 S.L. Antonsen et al. / Gynecologic Oncology 128 (2013) 300–308glucose-metabolism of malignant tumor cells. The potential value of
PET/CT for staging of EC has not yet been established.
In expert hands, transvaginal two-dimensional ultrasound (2DUS)
has shown good accuracy in local staging of EC, comparable to that of
MRI performed by radiologists specialized in gynecological imaging [7].
The aim of this prospective multicenter study was to evaluate and
compare the diagnostic performance of PET/CT, MRI and 2DUS in pre-
operative staging of EC with special focus on MI, CI and LNM.
Methods
Patients with a histological diagnosis of EC or atypical endometrial
hyperplasia (AEH)were consecutively invited to participate in the Danish
endometrial cancer study (ENDOMET). They were referred to the gy-
necologic clinics at University Hospitals in Copenhagen (Rigshospitalet),
Odense, and Aalborg for surgery between September 1, 2009 and
January 1, 2012. All participants gave informed oral and written consent.
Patients with a preoperative diagnosis of AEH were included because
we previously found that up to 59% of these patients have coexisting
EC [8]. The patients were offered PET/CT, MRI and 2DUS examina-
tion 1–31 days prior to treatment. Exclusion criteria were: (1) claus-
trophobia, severe obesity or difficulties in co-operation; (2) severe
kidney-disease that contraindicated intravenous contrast-agents; and
(3) additional malignant disease, current or former. However, patients
with premalignant cancers, cured skin cancer of non-melanoma type
and former breast cancer were included. (4) Patients with certainimplanted magnetic objects were excluded from MRI and patients
with diabetes mellitus were excluded from PET/CT.
All women were treated according to the national guidelines
[9]: the standard care consists of total hysterectomy and bilateral
salpingo-oophorectomy (BSO). Additionally, lymphadenectomy is
recommended for all patients except low-risk (stage I, b50%MI,
endometrioid histology, grades 1–2). Stage II patients (CI) are rec-
ommended radical hysterectomy, BSO and pelvic lymphadenectomy
while stage III/IV patients should have optimal debulking. Furthermore,
patients with type 2 histology (serous or clear cell adenocarcinomas)
are recommended omentectomy. Patients with stage III and IV disease
are recommended adjuvant chemotherapy. Few patients with dissemi-
nated disease or poor candidates for surgery are referred to primary
chemotherapy. Patients with AEH are treated as low-risk EC patients.
The uterus, fallopian tubes, and ovaries were sent for intraoperative
gross evaluation by pathologists with special expertise in gynecologi-
cal pathology. The surgical specimens were postoperatively evaluated
thoroughly and the results were registered in the Danish Gynecological
Cancer Database (DGCD) [10]. The International Federation of Gynecol-
ogy andObstetrics (FIGO) 2009 criteria [11]were used. The pathological
data were used as the reference standard.
Imaging
Scans were prospectively evaluated by one expert in Nuclear Medi-
cine at each center, one experienced radiologist at each center and one
expert in Gynecologic ultrasound. PET/CT scans were reviewed by a
nuclear medicine and a radiologist together. Scans were performed
according to the sameprotocol at all centers. The experts had no knowl-
edge about the results of the other scans or the pathological assessment
of the specimen. Either the PET/CT or the MRI scan was discussed at a
multi-disciplinary meeting at each center to plan further treatment.
PET/CT
At Rigshospitalet whole-body imaging was performed with a
Siemens Biograph 40 or 64, True Point PET/CT-scanner, at Odense
University Hospital a GE Discovery VCT or RX was used, and at
Aalborg University Hospital a GE Discovery STE or VCT was used.
CT and PET covered a region from the meatus of the ear to the prox-
imal thigh. The patient fasted for 6 h prior to PET acquisition. Sixty to
ninety minutes after injection of 370–400 MBq FDG in the cubital
vein, the CT scan was performed. All patients were asked to void be-
fore the scan. Oral and intravenous contrast-agents were given prior
to the diagnostic CT scan. Immediately thereafter the static emis-
sions were obtained in 2.5–4 min per field of view depending on
body mass index. The CT data were used for attenuation-correction
of the PET data. Images were reconstructed and stored in transaxial,
coronal and sagittal slices with a slice thickness of 2.5–3.3 mm. The
images were reviewed on a Siemens Leonardo PET/CT or a GE Advan-
tage workstation and findings suspicious of malignancy were recorded.
MRI
At Rigshospitalet MRI was performed using a Magnetom Espree
1.5 Tesla, in Odense a Philips Achieva 1.5 T system with combined
Torso and Cardiac coils was used, and in Aalborg a GE Sigma 1.5 T
twinspeed was used. MRI scans were performed using Spin-echo
T2, T1 and T2-Singleshot sequences in multiple planes, and T1 and
T1-SPIR perpendicular to long axis of uterus before and after admin-
istration of gadolinium based contrast agent. Lymph nodes with a
short-axis diameter larger than 10 mm were considered pathologic.
2DUS
All the ultrasound examinations were performed by using a GE
Voluson E8 Expert equipped with a multifrequency endovaginal probe
(5–9 MHz) at all centers. The examination was performed in the
lithotomic position with an empty bladder. After B-mode evaluation,
Table 2
Performance of PET/CT, MRI and 2DUS in predicting myometrial invasion, cervical invasion and lymph node metastases in endometrial cancer when performed individually.
Histology: myometrial invasion
≥50% b50% Total Sensitivity
(%)
(95% CI)
Specificity
(%)
(95% CI)
PPV
(%)
NPV
(%)
Accuracy
(%)
PET/CT 92.6 48.6 40.6 94.6 60.7
≥50% 63 92 155 (83.7–97.6) (38.3–76.5)
b50% 5 87 92
Total 68 179 247
MRI 87.3 57.3 44.0 92.2 65.6
≥50% 55 70 125 (76.5–94.3) (49.4–65.0)
b50% 8 94 102
Total 63 164 227
2DUS 71.4 71.7 50.6 86.1 71.6
≥50% 40 39 79 (58.8–82.7) (63.5–79.1)
b50% 16 99 115
Total 56 138 194
Histology: cervical invasion
Yes No Total Sensitivity
(%)
(95% CI)
Specificity
(%)
(95% CI)
PPV
(%)
NPV
(%)
Accuracy
(%)
PET/CT 42.9 94.3 68.6 85.0 82.7
Yes 24 11 35 (29.7–56.8) (90.0–97.1)
No 32 181 213
Total 50 192 248
MRI 33.3 94.5 60.0 85.1 82.3
Yes 15 10 25 (20.0–48.9) (90.1–97.3)
No 30 171 201
Total 45 181 226
2DUS 28.6 91.5 48.0 82.4 77.9
Yes 12 13 25 (15.7–44.6) (85.9–95.4)
No 30 140 170
Total 42 153 195
Histology: lymph node metastases
Yes No Total Sensitivity
(%)
(95% CI)
Specificity
(%)
(95% CI)
PPV
(%)
NPV
(%)
Accuracy
(%)
PET/CT 74.2 92.8 59.0 96.2 90.5
Yes 23 16 39 (53.4–88.2) (88.4–95.9)
No 8 205 213
Total 31 221 252
MRI 58.8 92.8 40.0 96.5 90.2
Yes 10 15 25 (32.9–81.6) (88.5–95.8)
No 7 193 200
Total 17 208 225
PPV: positive predictive value, NPV: negative predictive value.
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themyometrium and endometrium. The depth ofMI and CI was subjec-
tively evaluated.Statistics
All continuous data were expressed as median and range. Sensitiv-
ity, specificity, positive predictive value (PPV), negative predictive
value (NPV) and accuracy were calculated. The diagnostic accuracy
of PET/CT, MRI and 2DUS was compared using the McNemar test.
The probability of deep MI, CI and LNM was modeled using logistic
regression analysis with goodness of fit tested using the Hosmer–
Lemeshow test. Multivariate analysis included the three imaging
modalities, age, grade and histology (dichotomized clear cell/serous
versus endometrioid). Age was entered as a continuous covariate.
All other covariates are categorical variables. 95% confidence interval
limits were calculated using the exact method. p-Values less than
5% were considered significant. Statistical analyses were carried out
using Statistical Package for the Social Sciences (SPSS) software ver-
sion 19.0.This study was approved by the National Committee on Health
Research Ethics (protocol nr: H-A-2009-018) and the Danish Data
Protection Agency (j.nr. 2007-58-0015).
Results
A total of 464 women with EC or AEH were referred in the inclusion
period. Twenty-seven patients did not participate and 122 patients had
an exclusion criterion leaving 318 patients eligible for the study. A total
of 269 patients were PET/CT-scanned, 240 patients had MRI and 209
had 2DUS. 133 patients went through all three imaging modalities
(Fig. 1). Median age was 65 years (range 29–94), and 282 (88.7%)
were postmenopausal. Clinical characteristics are listed in Table 1.
Hysterectomy was performed in 307 (96.5%) women of whom 157
(51.1%) also underwent lymphadenectomy. Eleven patients (3.4%) were
upstaged by the preoperative imaging and biopsies and referred to che-
motherapy. Tumor had spread to the lymph nodes (pelvine, paraaotale,
inguinale, iliacale) in all patients, to the bones in three, to the bladder
or gut in three, to the neck in two, to the lungs in one, and as carcinosis
in the lower or upper abdomen in five patients. Final pathology diag-
nosed 18 patients with AEH. These were excluded from the subsequent
Table 3
Performance of PET/CT, MRI and 2DUS in predicting myometrial invasion, cervical invasion and lymph node metastases in endometrial cancer when performed on the same
patients.
Histology: myometrial invasion
≥50% b50% Total Sensitivity
(%)
(95% CI)
Specificity
(%)
(95% CI)
PPV
(%)
NPV
(%)
Accuracy
(%)
PET/CT 88.9 43.5 44.4 92.0 63.9
≥50% 32 40 72 (73.9–96.9) (42.4–64.3)
b50% 4 46 50
Total 36 86 122
MRI 88.9 57.0 46.4 92.6 66.7
≥50% 32 37 69 (73.9–96.9) (45.9–67.6)
b50% 4 50 54
Total 36 87 123
2DUS 69.4 74.4 53.2 85.5 73.2
≥50% 25 22 47 (71.9–83.6) (63.9–83.2)
b50% 11 65 76
Total 36 87 123
Histology: cervical invasion
Yes No Total Sensitivity
(%)
(95% CI)
Specificity
(%)
(95% CI)
PPV
(%)
NPV
(%)
Accuracy
(%)
PET/CT 38.5 92.8 62.5 84.1 81.3
Yes 10 6 16 (20.2–59.4) (85.7–97.1)
No 17 90 107
Total 27 96 123
MRI 26.9 93.8 58.3 82.7 80.3
Yes 7 5 12 (11.6–47.8) (87.0–97.7)
No 19 80 99
Total 26 85 111
2DUS 19.2 93.8 54.5 81.3 78.9
Yes 6 5 11 (7.6–39.3) (87.0–97.7)
No 21 91 112
Total 27 96 123
Histology: lymph node metastases
Yes No Total Sensitivity
(%)
(95% CI)
Specificity
(%)
(95% CI)
PPV
(%)
NPV
(%)
Accuracy
(%)
PET/CT 85.7 91.7 44.4 98.2 90.8
Yes 12 15 27 (67.2–98.2) (86.6–95.3)
No 3 166 169
Total 15 181 196
MRI 57.1 93.3 38.1 96.6 90.3
Yes 8 13 21 (28.9–83.3) (88.6–96.5)
No 6 168 174
Total 14 1681 195
PPV: positive predictive value, NPV: negative predictive value.
Table 4
Models for optimizing predictive value of myometrial invasion, cervical invasion and
lymph node metastases in endometrial cancer patients.
Imaging Sensitivity
(%)
Specificity
(%)
PPV
(%)
NPV
(%)
Accuracy
(%)
Myometrial invasion
PET/CT+MRI+2DUS 100 27.8 38.7 100 50.4
PET/CT+MRI 100 35.1 37.0 100 53.0
PET/CT+2DUS 95.7 35.7 41.7 94.6 55.2
MRI+2DUS 95.7 45.2 43.6 95.9 60.7
Cervical invasion
PET/CT+MRI+2DUS 46.2 81.3 40.0 84.8 73.8
PET/CT+MRI 51.3 89.8 55.6 88.1 82.1
PET/CT+2DUS 45.2 86.8 48.7 85.2 77.8
MRI+2DUS 40.5 87.5 47.2 84.2 77.3
Lymph node metastases
PET/CT+MRI 85.7 88.2 37.5 98.8 88.6
PPV: positive predictive value, NPV: negative predictive value.
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with AEH had false positive findings on imaging; one patient was diag-
nosed with MI ≥50% and LNM of 12 mm on MRI, two were diagnosed
with MI≥50% on MRI, another one on PET/CT and yet another on 2DUS.
The diagnostic performances of PET/CT, MRI and 2DUS in predicting
the depth of MI, CI and LNM are shown in Table 2.
When assessing invasion of the serosa, the sensitivities of PET/CT,
MRI and 2DUS were 75%, 67% and 67%, respectively, specificities were
90%, 90% and 96%, respectively, and the accuracies were 90%, 90% and
95%, respectively (data not shown).
For comparing the three imagingmodalities, calculationswere done
on the subgroup of women that had undergone the same three scan-
ning modalities (n=133). Results are shown in Table 3. For prediction
of MI we found significantly higher sensitivities for PET/CT and MRI
compared to 2DUS (89% and 89% vs. 69%), while 2DUS had significantly
higher specificity (44% and 57% vs. 74%).
For CI the imagingmodalities had similar high specificities (93%, 94%
and 94%) and accuracies (81% (PET/CT), 80% (MRI) and 79% (2DUS),
respectively). The sensitivities, however, were low but not significantly
different. For prediction of LNM there was no difference in accuracy
Table 5
Stage Lymph
nodes
Parametria/
adnexae
Other Pelvic LN
visualized
Paraaortal
LN
visualized
Other MRI findings Other PET/CT findings Stage
MRI
Stage
PET/CT
IIIA AD Not
scanned
Not
scanned
IIIA AD IB IB
IIIA AD IB II
IIIA AD Diaphragm IB IVB
IIIA Fossa douglasii PET/CT PET/CT,
MRI
Intestine, parametria,
adnexae
Intestine IVA IVA
IIIA AD Adnexae Not
scanned
IIIA*
IIIB PA Intestinal/rectal
involvement
IVA II
IIIB PA Vagina Bladder, parametria,
adnexae
Intestinal, bladder, vagina IVA IIIB*
IIIB PA, AD Peritoneum in pelvis,
parametria, vagina,
adnexae
Peritoneum in pelvis, parametria, adnexae IIIB* IIIB*
IIIB PA IIIA IA
IIIB PA IA IA
IIIB PA, AD PET/CT Parametria, adnexae Adnexae IIIB* IIIC2
IIIC1 PE Not
scanned
II
IIIC1 PE IA Not
scanned
IIIC1 PE PA Adnexae Not
scanned
IIIA
IIIC1 PE PET/CT Not
scanned
IIIC1*
IIIC1 PE PET/CT,
MRI
IIIC1* IIIC1*
IIIC1 PE MRI IIIC1* IB
IIIC1 PE IB IB
IIIC1 PE Not
scanned
IIIA
IIIC1 PE PET/CT Not
scanned
IIIC1*
IIIC1 PE PA Adnexae IB IIIA
IIIC1 PE MRI IIIC1* Not
scanned
IIIC1 PE PET/CT Not
scanned
IIIC1*
IIIC1 PE PET/CT IB IIIC1*
IIIC1 PE AD Not
scanned
IB
IIIC1 PE PET/CT,
MRI
Bladder IIIC1* IIIC1*
IIIC1 PE PET/CT Not
scanned
IIIC1*
IIIC2 PE Other PET/CT PET/CT Lymph nodes in mediastinum and lung hili
— suspicion of sarcoidosis
IA IIIC2*
IIIC2 PE, AO PET/CT,
MRI
PET/CT,
MRI
IIIC2* IIIC2*
IIIC2 PE, AO II II
IIIC2 AO PET/CT,
MRI
PET/CT,
MRI
Peritoneum in pelvis, parametria, adnexae IIIC2* IVB
IIIC2 PE, AO PA, AD PET/CT Colon sigmoideum Not
scanned
IVA
IIIC2 PE, AO PET/CT,
MRI
IIIC1 IIIC1
IIIC2 PE, AO Vagina PET/CT,
MRI
PET/CT Adnexae IIIC1 IIIC2*
IIIC MRI MRI Bladder, vagina,
parametria
IVA Not
scanned
IVA PA, AD Omentum Not
scanned
Not
scanned
IVA Omental II IA
IVB Carcinosis, omentum,
diaphragm
Retrosternal lymph
nodes, diaphragm,
peritoneum, omentum,
adnexae
Thoratical metastases, diaphragm,
peritoneum, omentum, appendix,
intestines, adnexae
IVB IVB*
IVB Lung metastases Lung metastases IA IVB*
IVB PA, AD Omental, spleen, intestinal,
paracolic space,
ligamentum falciforme,
diaphragm
MRI Parametria, adnexae IIIC Not
scanned
(continued on next page)
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Table 5 (continued)
Stage Lymph
nodes
Parametria/
adnexae
Other Pelvic LN
visualized
Paraaortal
LN
visualized
Other MRI findings Other PET/CT findings Stage
MRI
Stage
PET/CT
IVB Lung metastases Lung metastases IA IVB*
IVB PE PA, AD Omental PET/CT,
MRI
MRI Intestinal, bladder,
parametria, vagina,
adnexae
Carcinosis, omental, intestinal, bladder,
parametria, adnexae
IVB* IVB*
IVB PA Vagina, bone, bladder,
other
PET/CT,
MRI
PET/CT Left os ilium, bladder,
vagina, adnexae
Bone, bladder, vagina, adnexae IVB* IVB*
IVB Lung metastases MRI Parametria Lung metastases IIIC1 IVB*
IVB PE, AO PA, AD Rectum, vagina, omentum,
peritoneal carcinosis
PET/CT,
MRI
PET/CT,
MRI
Carcinosis, peritoneum,
omentum, parametria,
adnexae
Bone, diaphragm, carcinosis, peritoneum,
omentum, intestine, adnexae
IVB* IVB*
IVB AO PA Yes PET/CT PET/CT Inguinal metastases Not
scanned
IVB*
IVB PE, AO Other Not
scanned
Not
scanned
IVB PE, AO PA, AD Omentum, other PET/CT PET/CT Diaphragm, carcinosis, peritoneum,
omentum, adnexae
Not
scanned
IVB*
IVB PE, AO PA, AD Other PET/CT PET/CT Adnexae, other Not
scanned
IVB*
IVB PE, AO AD Diffuse carcinosis, inguinal
lymph nodes
PET/CT PET/CT Adnexae, peritoneum in pelvis, carcinoses,
metastases to Virchow's gland, lymph node
in med. sup. ant. and pericardial lipid
Not
scanned
IVB*
IVB PE, AO PA, AD Vagina, lung/thorax, other PET/CT PET/CT Bladder, metastases to cervical column and
right os ilium
Not
scanned
IVB*
IVB AO Lungs PET/CT Bowel, multiple lung metastases, Not
scanned
IVB*
IVB PE, AO AD Other PET/CT PET/CT Bone Not
scanned
IVB*
LN: lymph node, PE: pelvic; AO: paraaortal, PA: parametria, AD: adnexae.
* correct stage.
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(86%) thanMRI (57%), but the differencewas not significant (p=0.14).
For the sub-group of patients with grades 1–2 endometrioid tumors
(n=220) the results for predictingMI were similar to the overall study
group: Sensitivity, specificity, PPV, NPV and accuracy for PET/CT were
92%, 47%, 39%, 94% and 59%. For MRI they were 86%, 58%, 42%, 93%
and 66%, and for 2DUS 73%, 76%, 57%, 86% and 75%.
The results of the logistic regression analysis regarding prediction of
deepMI showed that neither histology (p=0.96), grade (p=0.84) nor
age (p=0.53) was significant, thus these variables were removed from
themodel. The final regressionmodel for deepMI included all three im-
aging modalities and the odds ratio (OR) with 95% confidence interval
(95% CI) and p-values were: 4.71 (1.39–15.90), p=0.013 (PET/CT);
5.38 (1.61–18.00), p=0.006 (MRI); and 3.91 (1.50–10.16), p=0.005
(2DUS). No interactions between the modalities could be demonstrat-
ed. The area under the ROC curve (AUC) for the final MI regression
model was 0.840. For prediction of CI, the results demonstrated that
neither histology (p=0.35), grade (p=0.21) nor age (p=0.25) was
significant. The final model showed that PET/CT had significant influ-
ence on the risk of CI (OR=5.67 (95% CI: 1.73–18.55), p=0.004)
whereas MRI (OR=3.09 (95% CI: 0.79–12.05), p=0.10) and 2DUS
(OR=1.57 (95% CI: 0.34–7.33), p=0.57) had not. The AUC of the
final model for CI was 0.670. Finally analysis was performed for predic-
tion of LNM. Grade and age were not significantly associated with
risk of LNM (p=0.58 and p=0.85, respectively), but histology was
(OR=28.34 (95% CI: 1.50–536.68), p=0.026). PET/CT was significant
(OR=30.53 (95% CI: 3.88–240.31), p=0.001) whereas MRI was not
(OR=0.76 (95% CI: 0.26–2.20), p=0.61). The AUC was 0.945. Remov-
ing histology resulted in similar OR for PET/CT and an AUC of 0.862 for
detecting LNM.
As we found that all of the imaging modalities were independently
predictive for MI, we combined the imaging results. The combined
models reached excellent sensitivities but low specificities (Table 4).
Among the 229 patients with b50% MI, 11 (4.8%) had LNM. The
histology of these 11 patients was four endometrioid adenocarcinomas,
five serous adenocarcinomas, one clear cell adenocarcinoma and onecarcinosarcoma/sarcoma. Of the 35 patients with LNM, only 19% had
grade 3 tumors and 31% were type 2 histology. Extra-uterine disease
among the 55 patients with stage III–IV tumors and imaging-findings
are shown in Table 5. PET/CT staged the patients correctly and found ex-
tra-uterine metastases more often than MRI did (57% vs. 32%). In three
patients lung-metastases were found on PET/CT.Discussion
A non-invasive preoperative technique that accurately stages EC
patients would be beneficial in improving tailored treatment and
minimizing costs. The knowledge of tumor-extension influences the
decision whether to perform a more radical hysterectomy with pelvic
and/or paraaortic lymphadenectomy.
To our knowledge, this study is the first to compare PET/CT, MRI and
2DUS in the preoperative evaluation of EC patients. We found PET/CT
and MRI to be equally good in predicting MI. 2DUS was not as sensitive
as the other modalities even though performed by specialists, but had
the highest accuracy (73%). Preoperative prediction of MI is essential
as deep MI increases the risk of LNM which worsens the prognosis.
For patients with b50% MI that could avoid lymphadenectomy, PET/CT
evaluated 51% and MRI 43% as deep invasion why too many patients
would have had lymphadenectomy if assessed by PET/CT or MRI
alone. Conversely, if PET/CT or MRI predicted b50% MI, this was correct
in 94% and 92% of the patients. The high NPV of PET/CT andMRI also in-
cluded the sub-group of grade 1–2 endometrioid tumors that may ben-
efit from less extensive surgery or occasionally avoid surgery altogether
(for fertility sparing or the very unfit). Therefore, they could be used in
excluding deep MI. These findings are supported by Cade et al. [12].
We only found one small retrospective study assessing MI by
PET/CT. They found 83% sensitivity and 88% specificity that were similar
to that of their MRI scans [13]. Several studies have evaluated the accu-
racy for MRI and 2DUS in predicting MI. Sensitivities range from 50 to
89% and specificities from 81 to 100% [7,14–20]. The differences may
reflect the different study populations, study-designs and sample size.
307S.L. Antonsen et al. / Gynecologic Oncology 128 (2013) 300–308MRI and PET/CT are costly, not always available and require contrast
agents. 2DUS, in contrast, is a simple, fast, and low-cost technique forMI
assessment. In addition, as technology has evolved, the diagnostic accu-
racy of 2DUS has become as high as MRI in several studies [7,21–23].
The sensitivities of 2DUS in our studywere not as high as those reported
in some studies [7,24], but comparable to those in others [25,26]. Most
studies are smaller and retrospective. The results of this study showed
that the ultrasonographic assessment of MI may not be as reliable as
previously suggested. Application of 3D ultrasound and power Doppler
angiography has been studied in gynecological oncology and shown
promising in experienced hands [27].
In our study, none of the imaging modalities were sensitive in
predicting CI. However, they were acceptable in excluding CI with
specificities around 95%. Literature findings are diverging. Sensitivi-
ties for MRI range from 19 to 100% and specificities from 87 to
100% [5,7,16,19,20,28–30]. The low sensitivity reported may be due
to inclusion of EC with only endocervical glandular involvement
(formerly staged as IIA), which is often undetectable on MRI [30].
Most authors have findings similar to ours. For 2DUS, Akbayir et al.
found high diagnostic accuracy for prediction of CI (98%) [21] and
Szantho et al. found accuracy of 70% [31].
In predicting LNM, Horowitz et al. found only moderate sensitiv-
ity (60%) but high specificity (98%) [32]. Signorelli et al. found that
PET/CT was an accurate method with 78% sensitivity, 100% specifici-
ty, and 94% accuracy [33] in agreement with Nakamura et al. [34]. In
contrast, Park et al. showed moderate sensitivity and concluded that
PET/CT cannot replace surgical staging [35]. The reported sensitivity
of MRI for detection of LNM in EC is generally low, ranging from 17 to
80% [30]. Inubashiri et al. compared FDG-PET with CT and MRI and
found no significant differences in their ability of diagnosing LNM.
They equally presented low sensitivity and high specificity [36].
Park et al. found, like us, that PET/CT showed higher sensitivity
than MRI in detecting LNM (46% vs. 69%) but it did not reach signif-
icant differences [35].
In our series, four low-risk patients had LNM. These patients
would in most centers not have had lymphadenectomy if the metas-
tases were not visualized at preoperative imaging. In low-risk pa-
tients the incidence of LNM is 0–10% [37]. Studies have shown that
lymphadenectomy can induce complications and may not increase
survival of low-risk EC patients [1,2]. Therefore, it is unethical to
stage low-risk patients with systematic lymphadenectomy. Imaging
with high NPV can help exclude deep MI and thereby support the de-
cision of avoiding lymphadenectomy in these patients. Furthermore,
11 patients were upgraded to stage IVB solely by imaging and were
referred to chemotherapy. This fact supports the need for preopera-
tive imaging. The question of the best preoperative staging modality
for determining extent of MI and thereby the risk of extra-uterine dis-
ease remains unsolved, although we found PET/CT most reliable in
preoperative staging of EC patients.
The strength of our study is that it consists of the largest series of
patients in the literature. The distribution of patients reflects the
background population. Furthermore, the prospective study-design
decreased risk of bias and the results are hereby transferable to
other clinics.
There were some limitations too. The fact that only 133 out of 318
patients underwent all imaging modalities decreased the power. Nev-
ertheless, it reflected the challenges in every-day work with EC pa-
tients who suffer from various co-morbidities. Another limitation
was that not all patients were fully staged which gives us a bias of
false negative lymph nodes. Furthermore, we included 11 patients
who were not hysterectomized, but were referred to chemotherapy.
This fact could prompt false positive stage IV patients. Finally, the sur-
geons were guided by preoperative imaging findings, and this may
have resulted in verification bias.
PET/CT, MRI and 2DUS did not reach high sensitivities in assessing
EC preoperatively. None of the modalities can yet replace surgicalstaging. However, they all contributed to important knowledge in
the preoperative staging, and they can be combined to improve accu-
racy. With these results in mind gynecological oncology surgeons
may use the imaging in assistance to their clinical guidelines. Due to
its high NPV in predicting MI and LNM, PET/CT and MRI can be useful
in selected patients who are poor candidates for surgical staging. PET/
CT was the most reliable of the three scanning modalities with regard
to prediction of MI, CI and LNM.
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